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S u m m a r y  
 
I n t r o d u c t i o n .  Chronic graft-versus-host disease 
(GVHD) is a life-threatening complication after allogeneic 
hematopoietic stem cell transplantation. Mesenchymal stem 
cells (MSC) are involved in tissue repair and modulating 
immune responses. We present report of two cases of use of 
third-party donor mesenchymal stem cells in the therapy of 
steroid-resistant chronic GVHD. 
C a s e  r e p o r t s .  The doses of MSC in both patients 
were 1.08 and 1.4 x 106 cells per kg body weight 
respectively. Time from diagnosis of GVHD to infusion of 
MSC was 420 and 330 days, respectively. Both patients had 
single infusion of MSC. We did not observe any adverse 
effects after both infusions of MSC. We obtained initially a 
partial response and then complete response in the first 
patient and a partial response in the second patient. In the 
first patient we achieved improvement of skin involvement 
resulting in reduction of immunosuppression. In the second 
patient with scleroderma we  achieved only a minor 
improvement.  
C o n c l u s i o n .  Administration of MSC is a safe 
method and might by an effective therapy for patients with 




S t r e s z c z e n i e  
 
W s t ę p .  Przewlekła postać choroby przeszczep-
przeciwko-gospodarzowi (chronic graft-versus-host disease, 
GVHD) jest zagrażającym życiu powikłaniem po przesz-
czepieniu allogenicznych komórek krwiotwórczych. Mezen-
chymalne komórki macierzyste (MSC) mają znaczenie  
w procesach reparacji tkankowej oraz modulowania odpo-
wiedzi immunologicznej. W pracy przedstawiamy opis 
dwóch przypadków zastosowania MSC od dawcy niezwią-
zanego z pacjentem, tzw. third-party donor,  w terapii stero-
ido-opornej przewlekłej GVHD. 
O p i s  p r z y p a d k u .  Zastosowane dawki MSC  
u pacjentów wynosiły odpowiednio 1,08 oraz 1,4 x 106 
komórek na kg cc. Czas od rozpoznania GVHD do infuzji 
MSC wynosił odpowiednio 420 i 330 dni. U obydwu 
pacjentów dokonano pojedynczych infuzji MSC. U żadnego 
z nich nie obserwowano niepożądanych reakcji po zastoso-
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waniu MSC. U pierwszego pacjenta uzyskano początkowo 
częściową poprawę, a po kilku miesiącach remisję całkowitą 
wszystkich zmian związanych z GVHD. Dzięki temu 
możliwe było znaczne zredukowanie dawek leków immuno-
supresyjnych. U drugiego pacjenta uzyskano tylko przejś-
ciową nieznaczną poprawę stanu twardzinowej skóry.  
Wniosek: Zastosowanie MSC jest metodą bezpieczną  
i może być efektywną terapią u pacjentów z przewlekłą 
postacią choroby GVHD.     
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Chronic graft-versus-host disease (cGVHD) is an 
important complication after hematopoietic stem cell 
transplantation (HSCT), which might be associated 
with high transplant rate mortality (TRM) and 
reduction in quality of life of the otherwise cancer-free 
patients [1-3]. The main issue are patients who did not 
respond to first- and second-line therapy with 
combinations of corticosteroids and calcineurin 
inhibitors [4].  
Nowadays, no standard therapy of chronic 
refractory GVHD is available. In order to improve the 
prognosis of these patients new therapeutic approaches 
are being sought. One of them might be the use of 
mesenchymal stem cells (MSC). 
MSC are multipotent non-hematopoietic stem cells 
that can differentiate into fibroblasts, osteoblasts, 
chondrocytes and adipocytes [5-9]. They have been 
used to repair injured tissues. It is also believed that 
they have immunomodulatory properties, including 
inhibition of T cell proliferation, inhibition of the 
activity of cytotoxic T cells, inhibition of 
differentiation and maturation of dendritic cells, B cells 
and NK cells [10, 11]. MSC have been used for 
prophylaxis and treatment of acute GVHD, as well as 
for the treatment of refractory chronic GVHD [12-15]. 
In all these studies it was emphasized that the treatment 
of MSC is safe for the patient [15-17].  
For the evaluation of the response to the treatment 
of GVHD and organ scoring the National Institutes of 
Health (NIH) consensus criteria are being used 
worldwide [18]. These criteria distinguish severe, 
moderate and mild grades of cGVHD. As a definition 
of complete remission (CR), the resolution of all 
clinical manifestations of the involved organs is 
required. Good partial response (PR) is defined as 
reduction of more than 75% pathologic changes, PR is 
defined as reduction of more than 50% but less than 
75%, and minor PR as reduction of more than 25% but 
less than 50%. No response (NO) is defined as no 




In this paper we report two cases of use of third-
party donor mesenchymal stem cells in therapy of 
steroid-resistant chronic GVHD.  
 
Patient 1 
17-year old boy, diagnosed with severe aplastic 
anemia, after failure of immunoablative therapy, 
underwent bone marrow transplantation from HLA-
matched brother. Conditioning regimen consisted of 
cyclophosphamide 50 mg/kg/daily, days from -6 to -3 
and antithymocyte globulin (Thymoglobulin, 
Genzyme) 3,75 mg/kg total (divided into days -3 and -
2). Due to primary graft failure, he had another 
transplantation of peripheral blood hematopoietic stem 
cells from the same donor at day +35. For GVHD 
prophylaxis the patients received cyclosporine  
3 mg/kg/day and for prophylaxis of infectious 
complications ciprofloxacin, acyclovir and 
trimetoprim-sulfametoxazol. After successful 
hematological engraftment, he developed acute graft-
versus-host disease II grade, with progression to 
chronic GVHD, limited to the skin. He was treated 
with prednisolone and cyclosporine. However, 
periodically exacerbation of the GVHD was observed, 
and 18 months after transplantation he developed 
steroid-resistant skin and ocular GVHD, with 
involvement of 80% of skin surface and dry-eye 
syndrome. He experienced infectious complications 
and an increase of creatinine concentration. At this 
time, the decision of therapy with MSC was 
undertaken.  
After agreement of Local Bioethical Committee, 
third-party donor MSC (obtained from Polish Stem 
Cells Bank) were administered at the dose of 1.08x10
6
 
cells/kg body weight. No adverse effect were observed 
during and after the MSC transfusion. The patient 
continued therapy with steroids and cyclosporine.  
3 month later he presented slight improvement in skin 
symptoms and resolution of ocular symptoms (minor 
PR). At 6 months after MSC therapy, further 
improvement of skin changes was observed that 
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enabled to reduce immunosuppression (PR). At 9 
months after MSC therapy, all skin changes have 
resolved (CR).  
 
Patient 2 
16 year old boy, with relapsed acute lymphoblastic 
leukemia, underwent peripheral blood hematopoietic 
stem cell transplantation from HLA-matched sister. 
Conditioning regimen consisted of Total Body 
Irradiation (TBI), 12 Gy divided into 6 doses delivered 
over 3 days (days -6,-5,-4), and etoposide 60 mg/kg at 
day -3. For GVHD prophylaxis he received 
cyclosporine 3 mg/kg/day and for prophylaxis of 
infectious complications ciprofloxacin, acyclovir and 
trimetoprim-sulfametoxazol.  
Five months after transplantation, he developed 
chronic generalized sclerodermatous GVHD involving 
80% of skin, without preceding acute GVHD. He was 
initially treated with prednisolone and cyclosporine. 
Due to prednisolone-resistance, he was referred for 
phototherapy. No improvement was observed and 
patient's mobility deteriorated. At 15
th
 month after 
transplantation, the decision of therapy with 
mesenchymal stem cells was undertaken.  
After agreement of Local Bioethical Committee, 
third-party donor MSC were administered at the dose 
of 1.4x10
6
 cells/kg body weight. No adverse effect 
were observed during and after the MSC transfusion. 
The patient continued therapy with steroids and 
cyclosporine, as well as physiotherapy. At 3 and 6 
months afterward, he presented a slight improvement 
(minor PR). Then he was switched to sirolimus therapy 
with more pronounced improvement (PR). 
 
MSC infusion 
MSC were obtained from the Polish Stem Cell 
Bank (Polski Bank Komórek Macierzystych, 
Warszawa).  The MSC were derived from Wharton’s 
jelly (WJ) of umbilical cord from third party unrelated 
donors. Cells were frozen and transported in liquid 
nitrogen. Before MSC infusion, patients were pre-
medicated with hydrocortisone and clemastine. MSC 
were thawed in water bath and administered during  




Chronic GVHD significantly increases the 
morbidity and mortality after allogeneic hematopoietic 
stem cell transplantation [1, 2, 3, 19]. The treatment of 
chronic GVHD is still unsatisfactory, because only 
about 50% of patients respond to front-line therapy 
with steroids and calcineurin inhibitors [4, 20]. MSC, 
due to their unique immunomodulatory properties, 
could provide an alternative therapeutic method [10, 
11]. Initially, promising results of the treatment of 
acute GVHD were obtained [13, 14, 17]. Afterwards, 
Weng et al. reported outcomes of 19 patients treated 
with MSC for refractory chronic GVHD with a median 
dose 0.6 x 10
6
/kg body weight. They obtained a partial 
or complete response in 73.7% and reduction or 
discontinuation of immunosuppression in 71.4% of 
patients with oral mucosa, GI tract, liver and skin 
involvement [15].        
So far only 7 patients with acute GVHD were 
treated with MSC in Poland. The median dose was 1.5 
x 10
6
 cells per kg body weight and the median time 
from diagnosis of GVHD was 28 days. The number of 
infusion was from 1 to 4. Recently, another patient 
with chronic GVHD was treated with MSC. The 
authors achieved a partial or complete remission in 
four patients [21].     
Our report relates to the use of MSC in therapy of 
chronic steroid-resistant GVHD. The doses were 
comparable to those given by other authors and were 
respectively 1.08 and 1.4 x 10
6
 cells per kg body 
weight in the first and second patient and the time from 
diagnosis of GVHD to infusion of MSC was 
respectively 420 and 330 days in the first and second 
patient. The patients had a single infusion of MSC. We 
obtained initially PR and then CR in the first patient 
and PR in the second patient. In the first patient we 
have achieved improved skin and reduced 
immunosuppression. In the patient with scleroderma 
we have achieved only a minor improvement. Our 
patients received a single dose of MSC. It is suggested 
that clinical benefit might not depend on the number of 
MSC but it may be a result of a production of growth 
factors or temporary immunosuppression [15]. In other 
studies almost half of the patients had received a single 
dose of MSC, while the remaining patients have 
received 2-4 infusions [15, 21]. 
MSC are used in regenerative medicine because 
they can differentiate to several mesenchymal tissues. 
The use of MSC was described in hemorrhagic cystitis, 
thrombotic microangiopathy symptoms, and refractory 
cytopenias after HSCT [5-9]. The MSC have also 
immunomodulatory effect and low immunogenicity, 
thus MSC are useful in transplant setting. MSC can 
inhibit T-cell proliferation after stimulation by allo-
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antigens and mitogens and prevent cytotoxic T-cells 
activity [10, 11]. Weng et al. detected that analysis of 
lymphocyte subsets can help to assess whether MSC 
might participate in the amelioration of GVHD. They 
observed that the CD8+CD28+ cells decreased when 
the GVHD improved. In contrast, the CD8+CD28- 
cells and CD5+CD19+ cells increased after MSC 
infusions. Probably, CD8+CD28- cells served as 
regulatory cells to induce immune tolerance and 
CD5+CD19+ cells protected from autoimmunity by 
producing cytokines such as IL-10 [15, 22-24].  
In conclusion, our experience is that the infusion of 
third party donor WJ-derived MSC is a safe procedure 
with clinical effect that can ameliorate symptoms and 
allow a reduction of immunosuppressive treatment in 
patients, even though MSC were applied in very 
advanced phase of disease as an ultimate salvage 
therapy. In comparison to the published data, possibly 
earlier application can lead to better clinical response. 
Further studies concerning pathophysiology, optimal 
doses, number of infusions and time intervals as well 
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